Agilon Health (AGL) Stock News

agilon health (NYSE: AGL) announced on November 7, 2025 that the New York Stock Exchange issued a notice dated November 5, 2025 saying the company is no longer in compliance with the NYSE continued listing Price Criteria because the average closing price was under $1.00 over a consecutive 30 trading-day period ended November 4, 2025.

The notice does not have immediate impact on the listing, and the company said operations and SEC reporting are not anticipated to be affected. agilon intends to notify the NYSE by November 19, 2025 that it will remain listed and plans to pursue a reverse stock split to regain compliance, subject to stockholder approval at the 2026 annual general meeting.

agilon health (NYSE: AGL) reported third-quarter 2025 results and re-established full-year outlook on November 4, 2025. Q3 revenue was $1.44B (down 1% YoY) with gross loss $68M, net loss $110M and Adjusted EBITDA loss $91M. Total members stood at 618,000 (6% decline YoY) including 503,000 Medicare Advantage and 115,000 ACO REACH beneficiaries.

The company cited a $73M shortfall in 2025 risk adjustment revenue (including a 9-month true-up), a $20M Q3 impact from exited markets and expects exited-market impact of $60M for the year. Cash and marketable securities were $311M and total debt $35M. Management expects $30M of operating cost reductions in 2026 and reiterated 2025 revenue guidance of $5.81B–$5.83B with Adjusted EBITDA of ($270M)–($245M).

agilon health (NYSE: AGL) will release third quarter 2025 financial results after market close on Tuesday, November 4, 2025 and host a conference call at 4:30 p.m. ET to discuss results.

U.S. participants can dial (833) 470-1428, international participants can dial +1 (404) 975-4839 and reference participant code 291396. A simultaneous webcast and on-demand replay will be available in the Events & Presentations section of agilon's investor relations website.

agilon health (NYSE: AGL) announced its management team will participate in a fireside chat at the 2025 Jefferies Healthcare Services Conference. The presentation is scheduled for Tuesday, September 30 at 8:45am ET.

Investors can access the live webcast through the "Events & Presentations" section of agilon health's investor relations website. On-demand replays will be made available shortly after the presentation concludes.

agilon health (NYSE: AGL) reported challenging second quarter 2025 results, with total revenue declining 6% year-over-year to $1.39 billion. The company experienced significant headwinds, including a $66 million prior period development impact and an $85 million reduction in risk adjustment revenue. Total platform membership decreased to 614,000, including 498,000 Medicare Advantage members.

The company reported a net loss of $104 million compared to a $31 million loss in Q2 2024, and negative medical margin of $53 million versus positive $106 million in the prior year. Following these results and a leadership change with CEO Steven Sell stepping down, agilon has suspended its full-year 2025 guidance. The company maintains a solid capital position with $327 million in cash and marketable securities.

agilon health (NYSE: AGL) announced a significant leadership transition as CEO Steven Sell steps down from his roles as President, CEO, and Board Director. Ronald A. Williams, the company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman to lead the transition.

The Board has established an Office of the Chairman to manage interim operations and has initiated a search for a permanent CEO. The Office includes key executives such as the CFO, CMO, and other senior leaders. Additionally, the company has withdrawn its full year 2025 earnings guidance in conjunction with this leadership change.

Williams, a healthcare industry veteran and former Chairman and CEO of Aetna, will focus on driving operational improvements and supporting physician partners while the search for a new CEO is conducted.

agilon health (NYSE: AGL) has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close. The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results.

Participants can join the call by dialing (833) 470-1428 (U.S.) or +1 (404) 975-4839 (international) using code 938716. A simultaneous webcast will be available on the company's investor relations website, with an on-demand replay accessible after the call.

A new peer-reviewed study published in JAMA Health Forum reveals that senior patients under women physicians in agilon health's (NYSE: AGL) Value-Based Care model achieve equal or better clinical outcomes with reduced healthcare utilization compared to those under male physicians. The study analyzed nearly 900 primary care physicians (40% women) across 15 practice groups in seven states, examining data from 225,000 Medicare Advantage patients. Key findings show women physicians' patients had better diabetes management, fewer ER visits and hospitalizations, and higher composite Stars quality scores. Notably, the study found women physicians earned more per patient in the VBC model compared to male counterparts, effectively reversing the traditional gender pay gap. The research highlights how agilon's Total Care Model successfully transitions physicians from fee-for-service to value-based care, resulting in improved patient outcomes and healthier communities.

agilon health (NYSE: AGL) has released new research highlighting the effectiveness of their Value-Based Care (VBC) model in improving primary care access for Traditional Medicare patients. The study, published in Health Affairs Scholar, found that physicians who adopted agilon's VBC model saw 35% more new Traditional Medicare patients (8 additional patients per year) compared to those using fee-for-service models. VBC-adopting physicians also kept their practices open to new patients for nearly one additional month annually. The research analyzed data from 208 PCPs who adopted VBC and 3,657 who maintained fee-for-service models between 2019-2023. This study is particularly significant given the projected shortage of 57,000 primary care physicians by 2040 and the 29% decline in Medicare payments since 2001, which has led many physicians to limit Traditional Medicare patient intake.